Abstract
No public abstract is available from the verified source records.
Surbhi Shah
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Expert report on immune thrombocytopenia: current diagnostics and treatment—recommendations from an expert group from Austria, Germany, and Switzerland
10.1159/000529662 · 2023
American Society of Hematology 2019 guidelines for immune thrombocytopenia
10.1182/bloodadvances.2019000966 · 2019
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
10.1182/bloodadvances.2019000812 · 2019
Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape
10.1080/17474086.2025.2570332 · 2026
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
10.1016/s0140-6736(08)60203-2 · 2008
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
10.1016/s0140-6736(10)60959-2 · 2011
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
10.1111/bjh.15573 · 2018
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(14)61495-1 · 2015
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
10.1002/ajh.25125 · 2018
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
10.1182/blood.2024027336 · 2025
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
10.1016/s2352-3026(24)00139-x · 2024
No additional external references are available.